Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Atorvaliq (atorvastatin calcium) is the first and only FDA-approved oral liquid Suspension that is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.
Brand Name : Atorvaliq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2023
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Liqrev (sildenafil) is the PDE5 inhibitor and First and Only Ready-made FDA-approved Liquid Suspension is indicated for the treatment of pulmonary arterial hypertension.
Brand Name : Liqrev
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 21, 2023
Lead Product(s) : Sildenafil Citrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CMP Pharma's Potassium Phosphates Injection Receives FDA Shelf Life Extension for Specific Lots
Details : Potassium phosphate injection is a phosphate replacement that is used to treat or prevent hypophosphatemia (low phosphorus in the blood).
Brand Name : Potassium Phosphate-Geneic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 31, 2023
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tadliq is the first and only FDA-approved liquid oral suspension of tadalafil for adult patients with difficulty swallowing. Tadliq is indicated for the treatment of pulmonary arterial hypertension and ensures consistent dosing.
Brand Name : Tadliq
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : Tadalafil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Amlodipine Besylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Norliqva (Amlodipine) oral solution, 1 mg/mL, first and only FDA-approved oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker, for treatment of hypertension in patients 6 years of age and older.
Brand Name : Norliqva
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Amlodipine Besylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?